SEC and FTC open two more in­ves­ti­ga­tions in­to Bio­gen's con­tro­ver­sial Alzheimer's drug ap­proval and mar­ket­ing prac­tices

Fol­low­ing Bio­gen’s an­nounce­ment of minis­cule 2021 sales for its con­tro­ver­sial new Alzheimer’s drug yes­ter­day, the com­pa­ny al­so re­vealed that the Fed­er­al Trade Com­mis­sion and the Se­cu­ri­ties and Ex­change Com­mis­sion have opened two new, sep­a­rate in­ves­ti­ga­tions in­to the trou­bled biotech.

The FTC, an an­titrust reg­u­la­tor, has re­quest­ed doc­u­ments re­lat­ed to a civ­il in­ves­tiga­tive de­mand, sim­i­lar to a sub­poe­na, on the mar­ket­ing and ap­proval of the Alzheimer’s drug.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.